ArticleCrohn's & colitis 3602026

Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study.

Vipul Jairath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.